Degarelix, a new GnRH antagonist, in prostate cancer

Community Oncology

Volumn 6, Issue 5, 2009, Pages 197-199

  Stenger, Matt ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTHRALGIA; BACKACHE; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FATIGUE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INJECTION PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; PROSTATE CANCER; QT INTERVAL; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 66549108510     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70541-1     Document Type: Short Survey

References (3)

1. Gittelman M, Pommerville PJ, Persson B-E, Jensen J-K, Olesen TK. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. Degarelix Study Group. J Urol 2008;180:1986-1992.
2. Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomized, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-813.
3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-1538.